Postmenopausal hormone replacement therapy

Clinical Trials in Heart Disease: A Companion to Braunwald's Heart Disease

Volumn , Issue , 2004, Pages 349-363

  Chae, Claudia U ^a   Manson, JoAnn E ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33646763024     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7216-0408-4.50032-9     Document Type: Chapter

References (157)

1. U.S.Senate Special Committee on Aging Aging America: Trends and Projections 1988, US Department of Health and Human Services, Washington DC.
2. Heart and Stroke Facts. Dallas, American Heart Association, 1992.
3. Keating N, Cleary P, Aossi A, et al. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 1999, 130:545-553.
4. Kreling D, Mott D, Wiederholt J, et al. Prescription drug trends: A chartbook update 2001, Kaiser Family Foundation, Menlo Park, CA, November.
5. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998, 280:605-613.
6. Clarke SC, Kelleher J, Lloyd-Jones H, et al. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: The Papworth HRT atherosclerosis study. BJOG 2002, 109:1056-1062.
7. The ESPRIT team: Oestrogen therapy for prevention of reinfarction in postmenopausal women: A randomized placebo controlled trial. Lancet. Published online December 17, 2002. Accessed August 19, 2003. http://image.thelancet.com/extras/02art11268web.pdf.
8. Viscoli CM, Brass LM, Kernan WN, et al. A clinical trial of estrogen replacement therapy after ischemic stroke. N Engl J Med 2001, 345:1243-1249.
9. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med 2000, 343:522-529.
10. Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: A randomized controlled trial. JAMA 2002, 288:2432-2440.
11. Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333.
12. Walter P, Green S, Greene G, et al. Cloning of the human estrogen receptor cDNA. Proc Natl Acad Sci USA 1985, 82:7889-7993.
13. Kuiper GGJM, Enmark E, Pelto-Huikko M, et al. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996, 93:5925-5930.
14. Tsai MJ, O'Malley BW Molecular mechanisms of actions of steroid/thyroid receptor superfamily members, Ann Rev Biochem 1994, 63:451-486.
15. Matthews KA, Meilahn E, Kuller LH, et al. Menopause and risk factors for coronary artery disease. New Engl J Med 1989, 321:641-646.
16. Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991, 325:1196-1204.
17. Moorjani S, Dupont A, Labrie F, et al. Changes in lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with utrogestan in menopausal women. J Clin Endocrinol Metab 1991, 73:373-379.
18. Sacks FM, Walsh BW The effects of reproductive hormones on serum lipoproteins: Unresolved issues in biology and clinical practice. Ann NY Acad Sci 1990, 592:272-285.
19. Miller VT, Muesing RA, LaRosa JC, et al. Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein subfractions, and apoplipoprotein A-1. Obstet Gynecol 1991, 77:235-240.
20. The Writing Group for the PEPI Trial Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995, 273:199-208.
21. Lobo RA, Pickar JH, Wild RA, et al. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol 1994, 84:987-995.
22. Medical Research Council's General Practice Research Framework Randomized comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy. BMJ 1996, 312:473-478.
23. Speroff L, Rowan J, Symons J, et al. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART Study). JAMA 1996, 276:1397-1403.
24. Munk-Jensen N, Ulrich LG, Obel EB, et al. Continuous combined and sequential estradiol and norethindrone acetate treatment of postmenopausal women: Effect on plasma lipoproteins in a two-year placebo-controlled trial. Am J Obstet Gynecol 1994, 171:132-138.
25. Walsh BW, Sacks FM Effects of low dose oral contraceptives on very low density and low density lipoprotein metabolism. J Clin Invest 1993, 91:2126-2132.
26. Bostom AG, Gagnon DR, Cupples LA, et al. A prospective investigation of elevated lipoprotein(a) detected by electrophoresis and cardiovascular disease in women: The Framingham Heart Study. Circulation 1994, 90:1688-1695.
27. Orth-Gomér K, Mittleman MA, Schenck-Gustafsson K, et al. Lipoprotein(a) as a determinant of coronary heart disease in young women. Circulation 1997, 95:329-334.
28. Espeland MA, Marcovina SM, Miller V, et al. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. Circulation 1998, 97:979-986.
29. Shlipak MG, Simon JA, Vittinghoff E, et al. Estrogen and progestin, lipoprotein(a) and the risk of recurrent coronary heart disease events after menopause. JAMA 2000, 283:1845-1852.
30. Koh KK, Cardillo C, Bui MN, et al. Vascular effects of estrogen and cholesterol lowering therapies in hypercholesterolemic postmenopausal women. Circulation 1999, 99:354-360.
31. Darling GM, Johns JA, McCloud PI, et al. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med 1997, 337:595-601.
32. Herrington DM, Werbel BL, Riley WA, et al. Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease. J Am Coll Cardiol 1999, 33:2030-2037.
33. Adams MR, Kaplan JR, Manuck SB, et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys: Lack of an effect of added progesterone. Arteriosclerosis 1990, 10:1051-1057.
34. Wagner JD, Clarkson TB, St.Clair RW, et al. Estrogen and progesterone replacement therapy reduces low density lipoprotein accumulation in the coronary arteries of surgically postmenopausal cynomolgus monkeys. J Clin Invest 1991, 88:1995-2002.
35. Clarkson TB, Shively CA, Morgan TM, et al. Oral contraceptives and coronary artery atherosclerosis of cynomolgus monkeys. Obstet Gynecol 1990, 75:217-222.
36. Haarbo J, Leth-Espensen P, Stender S, et al. Estrogen monotherapy and combined estrogen-progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits. J Clin Invest 1991, 87:1274-1279.
37. Hanke H, Hanke S, Finking G, et al. Different effects of estrogen and progesterone on experimental atherosclerosis in female versus male rabbits: Quantification of cellular proliferation by bromodeoxyuridine. Circulation 1996, 94:175-181.
38. Mazière C, Auclair M, Ronveaux M-F, et al. Estrogens inhibit copper and cell-mediated modification of low density lipoprotein. Atherosclerosis 1991, 89:175-182.
39. Nègre-Salvayre A, Pieraggi M-T, Mabile L, et al. Protective effect of 17?-estradiol against the cytotoxicity of minimally oxidized LDL to cultured bovine aortic endothelial cells. Atherosclerosis 1993, 99:207-217.
40. Koh KK, Minemoyer R, Bui MN, et al. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997, 336:683-690.
41. Sack MN, Rader DJ, Cannon RO Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet 1994, 343:269-270.
42. Scarabin P-Y, Plu-Bureau G, Bara L, et al. Haemostatic variables and menopausal status: Influence of hormone replacement therapy. Thromb Haemost 1993, 70:584-587.
43. Scarabin P-Y, Vissac A-M, Kirzin J-M, et al. Population correlates of coagulation factor VII: Importance of age, sex, and menopausal status as determinants of activated factor VII. Arterioscler Thromb Vasc Biol 1996, 16:1170-1176.
44. Meade TW, Dyer S, Howarth DJ, et al. Antithrombin III and procoagulant activity: Sex differences and effects of the menopause. Br J Haematol 1990, 74:77-81.
45. The Writing Group for the Estradiol Clotting Factors Study Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: A 1-year, double-blind, placebo-controlled study. Thromb Haemost 1996, 75:476-480.
46. Kroon U-B, Silfverstolpe G, Tengborn L The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb Haemost 1994, 71:420-423.
47. Sporrong T, Mattsson L-A, Samsioe G, et al. Haemostatic changes during continuous oestradiol-progestogen treatment of postmenopausal women. Br J Obstet Gynaecol 1990, 97:939-944.
48. Mannucci PM, Giangrande PLF Detection of the prethrombotic state due to procoagulant imbalance. Eur J Haematol 1992, 48:65-69.
49. Caine YG, Bauer KA, Barzegar S, et al. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost 1992, 68:392-395.
50. Teede HJ, McGrath BP, Smolich JJ, et al. Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis, Arterioscler Thromb Vasc Biol 2000, 20:1404-1409.
51. Scarabin PY, Alhenc-Gelas M, Plu-Bureau, et al. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997, 17:3071-3078.
52. Walsh B, Kuller L, Wild R, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998, 279:1445-1451.
53. Herrington DM, Vittinghoff E, Howard TD, et al. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arterioscler Thromb Vasc Biol 2002, 22:1012-1017.
54. Rosendaal FR, Vessey M, Daly E, et al. Hormone replacement therapy, prothrombic mutations and the risk of venous thrombosis. Br J Haematol 2002, 116:851-854.
55. Ross R Atherosclerosis: An inflammatory disease. N Engl J Med 1998, 340:115-127.
56. Cushman M, Meilahn EN, Psaty BM, et al. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol 1999, 19:893-899.
57. Ridker PM, Hennekens CH, Rifai N, et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999, 100:713-716.
58. Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study Circulation 1999, 100:717-722.
59. Pradhan AD, Manson JE, Roussow JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: Prospective analysis from the Women's Health Initiative Observational Study. JAMA 2002, 288:980-987.
60. Decensi A, Omodei U, Robertson C, et al. Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. Circulation 2002, 106:1224-1228.
61. Despres J-P, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996, 334:952-957.
62. Farhat MY, Kavigne MC, Ramwell PW The vascular protective effects of estrogen. FASEB J 1996, 10:615-624.
63. Mendelsohn ME, Karas RH The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999, 340:1801-1811.
64. Reis SE, Gloth ST, Blumenthal RS, et al. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation 1994, 89:52-60.
65. Gilligan DM, Quyyumi AA, Cannon RO Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 1994, 89:2545-2551.
66. Collins P, Rosano GMC, Sarrel PM, et al. 17?-Estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 1995, 92:24-30.
67. Gilligan DM, Badar DM, Panza JA, et al. Acute vascular effects of estrogen in postmenopausal women. Circulation 1994, 90:786-791.
68. Mendelsohn ME Nongenomic estrogen receptor-mediated activation of endothelial nitric oxide synthase: How does it work? What does it mean?. Circ Res 2000, 87:677-682.
69. Chen Z, Yuhanna IS, Galcheva-Gargova Z, et al. Estrogen receptor a mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest 1999, 103:401-406.
70. Caulin-Glaser T, García-Cardeña G, Sarrel P, et al. 17?-Estradiol regulation of human endothelial cell basal nitric oxide release, independent of cytosolic Ca 2+ mobilization. Circ Res 1997, 81:885-892.
71. Razandi M, Pedram A, Greene GL, et al. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: Studies of ER-alpha and ER-beta expressed in Chinese hamster ovary cells. Mol Endocrinol 1999, 13:307-319.
72. Hardy SP, Valverde MA Novel plasma membrane action of estrogen and antiestrogens revealed by their regulation of a large conductance chloride channel. FASEB J 1994, 8:760-765.
73. White RE, Darkow DJ, Falvo Lang JL Estrogen relaxes coronary arteries by opening BK Ca channels through a cGMP-dependent mechanism. Circ Res 1995, 77:936-942.
74. Wellman GC, Bonev AD, Nelson MT, et al. Gender differences in coronary artery diameter involve estrogen, nitric oxide, and Ca 2+ dependent K + channels. Circ Res 1996, 79:1024-1030.
75. Chang W-C, Nakao J, Orimo H, et al. Stimulation of prostaglandin cyclooxygenase and prostacyclin synthetase activities by estradiol in rat aortic smooth muscle cells. Biochim Biophys Acta 1980, 620:472-482.
76. Weiner CP, Lizasoain I, Baylis SA, et al. Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci USA 1994, 91:5212-5526.
77. Hayashi T, Fukuto JM, Ignarro LJ, et al. Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: Implications for atherosclerosis. Proc Natl Acad Sci USA 1992, 89:11259-11263.
78. Binko J, Majewski H 17?-Estradiol reduces vasoconstriction in endothelium-denuded rat aortas through inducible NOS. Am J Physiol 1998, 274:H853-H859.
79. Gisclard V, Miller VM, Vanhoutte PM Effect of 17?-estradiol on endothelium-dependent responses in the rabbit. J Pharmacol Exp Ther 1988, 244:19-22.
80. Miller VM, Vanhoutte PM Progesterone and modulation of endothelium-dependent responses in canine coronary arteries. Am J Physiol 1992, 261:R1022-R1027.
81. Williams JK, Adams MR, Herrington DM, et al. Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J Am Coll Cardiol 1992, 20:452-457.
82. Guetta V, Quyyumi AA, Prasad A, et al. The role of nitric oxide in coronary vascular effects of estrogen in postmenopausal women. Circulation 1997, 96:2795-2801.
83. Hayashi T, Yamada K, Esaki T, et al. Estrogen increases endothelial nitric oxide by a receptor-mediated system. Biochem Biophys Res Commun 1995, 214:847-855.
84. Arnal JF, Clamens S, Pechet C, et al. Ethinylestradiol does not enhance the expression of nitric oxide synthase in bovine endothelial cells but increases the release of bioactive nitric oxide by inhibiting superoxide anion production. Proc Natl Acad Sci USA 1996, 93:4108-4113.
85. Keaney JF, Shwaery GT, Xu A, et al. 17?-Estradiol preserves endothelial vasodilator function and limits low-density lipoprotein oxidation in hypercholesterolemic swine. Circulation 1994, 89:2251-2259.
86. Lieberman EH, Gerhard MD, Uehata A, et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med 1994, 121:936-941.
87. Vekhavaara S, Hakala-Ala-Pietilä T, Virkamäki A, et al. Differential effects of oral and transdermal estrogen replacement therapy on endothelial function in postmenopausal women. Circulation 2000, 102:2687-2693.
88. Sudhir K, Ko E, Zellner C, et al. Physiological concentrations of estradiol attenuate endothelin 1-induced coronary vasoconstriction in vivo. Circulation 1997, 96:3626-3632.
89. Webb CM, Ghatei MA, McNeill JG, et al. 17?-Estradiol decreases endothelin-1 levels in the coronary circulation of postmenopausal women with coronary artery disease. Circulation 2000, 102:1617-1622.
90. Williams JK, Honoré EK, Washburn SA, et al. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J Am Coll Cardiol 1994, 24:1757-1761.
91. Sorenson KE, Dorup I, Hermann AP, et al. Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function. Circulation 1998, 97:1234-1238.
92. Wakatsuki A, Okatani Y, Ikenoue N, et al. Effect of medroxyprogesterone acetate on endothelium-dependent vasodilation in postmenopausal women receiving estrogen. Circulation 2001, 104:1773-1778.
93. Gerhard M, Walsh B, Tawakol A, et al. Estradiol therapy combined with progesterone and endothelial dependent vasodilation in postmenopausal women. Circulation 1998, 98:1158-1163.
94. Rosano GMC, Peters NS, Lefroy D, et al. 17-Beta estradiol therapy lessens angina in postmenopausal women with syndrome X. J Am Coll Cardiol 1996, 28:1500-1505.
95. Rosano GMC, Sarrel PM, Poole-Wilson PA, et al. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet 1993, 342:133-1336.
96. Holdright DR, Sullivan AK, Wright CA, et al. Acute effect of oestrogen replacement on treadmill performance in postmenopausal women with coronary artery disease. Eur Heart J 1995, 16:1566-1570.
97. Iafrati MD, Karas RH, Aronovitz M, et al. Estrogen inhibits the vascular injury response in estrogen receptor ?-deficient mice. Nat Med 1997, 3:545-548.
98. Lindner V, Kim SK, Karas RH, et al. Increased expression of estrogen receptor ? mRNA in male blood vessels after vascular injury Circ Res 1998, 83:224-229.
99. Sullivan TR, Karas RH, Aronovitz M, et al. Estrogen inhibits the response-to-injury in a mouse carotid artery model. J Clin Invest 1995, 96:2482-2488.
100. Chen S-J, Li H, Durand J, et al. Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery. Circulation 1996, 93:577-584.
101. Levine RL, Chen SJ, Durand J, et al. Medroxyprogesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of the rat carotid artery. Circulation 1996, 94:2221-2227.
102. Bourassa PAK, Milos PM, Gaynor BJ, et al. Estrogen reduces atherosclerotic lesion development in apolipoprotein-E deficient mice. Proc Natl Acad Sci USA 1996, 93:10022-10027.
103. Karas RH, Hodgin JB, Kwoum M, et al. Estrogen inhibits the vascular injury response in estrogen receptor ?-deficient mice. Proc Natl Acad Sci USA 1999, 96:15133-15136.
104. Bakir S, Mori T, Durand J, et al. Estrogen-induced vasoprotection is estrogen receptor dependent: Evidence from the balloon-injured rat carotid artery model. Circulation 2000, 101:2342-2344.
105. Oparil S, Levine RL, Chen S-J, et al. Sexually dimorphic response of the balloon-injured rat carotid artery to hormone treatment. Circulation 1997, 95:1301-1307.
106. Adams MR, Register TC, Golden DL, et al. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1997, 27:217-221.
107. Fischer GM, Swain ML Effects of estradiol and progesterone on the increased synthesis of collagen in atherosclerotic rabbit aortas. Atherosclerosis 1985, 54:1770-1785.
108. Morales DE, McGowan KA, Grant DS, et al. Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. Circulation 1995, 91:755-763.
109. Krasinski K, Spyridopoulos I, Asahara T, et al. Estradiol accelerates functional endothelial recovery after arterial injury. Circulation 1997, 95:1768-1772.
110. Spyridopoulos I, Sullivan AB, Keraney M, et al. Estrogen-receptor-mediated inhibition of human endothelial cell apoptosis. Circulation 1997, 95:1505-1514.
111. Caulin-Glaser T, Watson CA, Pardi R, et al. Effects of 17?-Estradiol on cytokine-induced endothelial cell adhesion molecule expression. J Clin Invest 1996, 98:36-42.
112. Grady D, Rubin SM, Pettiti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Int Med 1992, 117:1016-1037.
113. Grodstein F, Stampfer M The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 1995, 38:199-210.
114. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996, 335:453-461.
115. Jick H, Derby LE, Myers MW, et al. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996, 348:981-983.
116. Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996, 348:977-980.
117. Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996, 348:983-987.
118. Sullivan JM, Vander Zwaag R, Hughes JP, et al. Estrogen replacement and coronary artery disease: Effect on survival in postmenopausal women. Arch Intern Med 1990, 150:2557-2562.
119. O'Keefe JH, Kim SC, Hall RR, et al. Estrogen replacement therapy after coronary angioplasty. J Am Coll Cardiol 1997, 29:1-5.
120. Sullivan JM, El-Zeky F, Zwaag Z, et al. Effect on survival of estrogen replacement therapy after coronary artery bypass grafting. Am J Cardiol 1997, 79:847-850.
121. Shlipak MG, Angeja BG, Go AS, et al. Hormone therapy and in-hospital survival after myocardial infarction in postmenopausal women. Circulation 2001, 104:2300-2304.
122. Grodstein F, Manson JE, Stampfer MJ Postmenopausal hormone use and secondary prevention of coronary events in the Nurses' Health Study: A prospective observational study. Ann Intern Med 2001, 135:1-8.
123. Heckbert SR, Kaplan RC, Weiss NS, et al. Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy. Arch Intern Med 2001, 1709-1713.
124. Col NF, Eckman MH, Karas RH, et al. Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA 1997, 277:1140-1147.
125. Cummings SR, Black DM, Rubin SM Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 1989, 149:2445-2448.
126. Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997, 350:1047-1059.
127. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and risk of coronary heart disease. N Engl J Med 2003, 349:523-534.
128. Fletcher SW, Colditz GA Failure of estrogen plus progestin therapy for prevention. JAMA 2002, 288:366-367.
129. MRC stops study of long-term use of HRT. London: MRC press release, Accessed January 6 2003. http://www.mrc.ac.uk/index/public-interest/public-press_office/public-press_releases_2002/public-23_october_2002.htm.
130. Furberg CD, Vittinghoff E, Davidson M, et al. Subgroup interactions in the Heart and Estrogen-progestin Replacement Study: Lessons learned. Circulation 2002, 105:917-922.
131. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estro-gen/progestin Replacement Study follow-up (HERS II). JAMA 2002, 288:49-57.
132. Nabel EG Coronary heart disease in women: An ounce of prevention. N Engl J Med 2000, 343:572-574.
133. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001, 135:939-953.
134. Angerer P, Störk S, Kothny W, et al. Effects of postmenopausal hormone replacement on progression of atherosclerosis: A randomized, controlled trial. Arterioscler Thromb Vasc Biol 2001, 21:262-268.
135. Schulman SP, Thiemann DR, Ouyang P, et al. Effects of acute hormone replacement therapy on recurrent ischemia on postmenopausal women with unstable angina. J Am Coll Cardiol 2002, 39:231-237.
136. Simpkins JW, Rajakumar G, Zhang Y, et al. Estrogens may reduce mortality and ischemic damage caused by middle cerebral artery occlusion in the female rat. J Neurosurg 1997, 87:724-730.
137. Yang SH, Shi J, Day AL, et al. Estradiol exerts neuroprotective effects when administered after ischemic insult. Stroke 2000, 31:745-750.
138. Simon JA, Hsia J, Cauley JA, et al. Postmenopausal hormone replacement therapy and risk of stroke: The Heart and Estrogen-progestin Replacement Study (HERS).Circulation 2001, 103:638-642.
139. Mendelsohn ME, Karas RH The time has come to stop letting the HERS tale wag the dogma. Circulation 2001, 104:2256-2259.
140. Hanke H, Kamenz J, Hanke S, et al. Effect of 17-beta estradiol on preexisting atherosclerotic lesions: Role of the endothelium. Atherosclerosis 1999, 147:123-132.
141. Holm P, Andersen HL, Andersen MR, et al. The direct antiatherogenic effect of estrogen is present, absent, or reversed, depending on the state of the arterial endothelium: A time course-study in cholesterol-clamped rabbits. Circulation 1999, 100:1727-1733.
142. Mosca L, Collins P, Herrington DM, et al. Hormone replacement therapy and cardiovascular disease: A statement for healthcare professionals from the American Heart Association. Circulation 2001, 104:499-503.
143. Herrington DM The HERS trial results: Paradigms lost?. Ann Intern Med 1999, 131:463-466.
144. Blakely JA The Heart and Estrogen/Progestin Replacement Study revisited: Hormone replacement therapy produced net harm, consistent with the observational data. Arch Intern Med 2000, 160:2897-2900.
145. Herrington DM, Howard TD, Hawkins GA, et al. Estrogen receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med 2002, 346:967-974.
146. Herrington DM, Howard TD, Brosnihan B, et al. Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation 2002, 105:1879-1882.
147. U.S.Preventive Services Task Force Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: Recommendations and rationale. Ann Intern Med 2002, 137:834-839.
148. American Heart Association: Q & A about hormone replacement therapy. Accessed January 6, 2003. http://216.185.112.5/presenter.jhtml?identifier=3004068.
149. North American Menopause Society: Amended report from the NAMS advisory panel on postmenopausal hormone replacement therapy. Accessed December 9, 2002. http://www.menopause.org/news.html#advisory.
150. American College of Obstetricians and Gynecologists Guidelines for Women's Health Care 2002, 130-133. ACOG, Washington, DC, 171-176, 314-318. 2nd ed.
151. FDA Approves New Labels for Estrogen and Estrogen with Progestin Therapies for Postmenopausal Women Following Review of Women's Health Initiative Data. Accessed January 10, 2003. http://www.fda.gov/cder/drug/infopage/estrogens_progestins/default.htm.
152. Fuchs-Young R, Glasebrook AL, Short LL, et al. Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor. Ann NY Acad Sci 1995, 761:355-360.
153. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997, 337:1641-1647.
154. De Valk-de Roo GW, Stehouwer CD, Meijer P, et al. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled trial. Arterioscler Thromb Vasc Biol 1999, 19:2993-3000.
155. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002, 287:847-857.
156. Bjarnason NH, Haarbo J, Byrjalsen I, et al. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. Circulation 1997, 96:1964-1969.
157. Clarkson TB, Anthony MS, Jerome CP Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab 1998, 83:721-726.